U.S., Oct. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07215494) titled 'A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis' on Oct. 02.
Brief Summary: Before effective treatment, the prognosis of patients with AL amyloidosis is very poor, with a median survival of approximately 12 months. In recent decades, with the development of new drugs, the treatment paradigm for AL amyloidosis has undergone significant changes, and the prognosis has improved dramatically. Achieving very good partial response (VGPR) or even complete response (CR) can lead to higher organ response and longer survival. However, not all patients who achieve >=VGPR reach organ response, which...